More insight into effects of treatment with PCSK9 inhibition from 5 new FOURIER analyses
AHA 2017 - Anaheim, CA, USANov. 14, 2017 - Anaheim, CA, USA - Robert Giugliano - Boston, MA, USA
AHA 2017 Dr. Giugliano summarises findings of 2 additional clinical trial updates and studies into infarct size, TIMI stable IHD risk and total events in the FOURIER trial.
This 3-minute education provides a summary of just presented scientific data, recorded during the AHA 2017 congress. The objective is to provide a brief commentary and potential implications of these findings.
- Our reporting is based on the information provided at the AHA 2017 congress -
Marc Sabatine: Greater relative and absolute risk reduction in high-risk subgroup with previous MI treated with PCSK9 inhibition Marc Bonaca: Robust benefits for CV and limb event risk in PAD patients on PCSK9 inhibition